Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

On Wednesday, RBC Capital adjusted its outlook on CrowdStrike Holdings (NASDAQ:CRWD), increasing the price target to $420 from the ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Shares of Incyte Corporation INCY fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

Apr 14, 2023 1:48pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Incyte Corporation - INCY by Newsfile ...